JBMR Plus, 2019 Teriparatide, currently only available in brand form in the United States, is a costly drug approved for the treatment of postmenopausal osteoporotic women who are at high risk of fracture.
Takahiro Mori +2 more
doaj +1 more source
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide [PDF]
, 2010 Summary We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment.
A. Blumsohn +49 more
core +3 more sources
Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX [PDF]
, 2015 Summary The aim of this study was to determine the efficacy of once-weekly teriparatide as a function of baseline fracture risk. Treatment with once-weekly teriparatide was associated with a statistically significant 79 % decrease in vertebral ...
A. Odén +29 more
core +2 more sources
Acta Orthopaedica, 2018 Background and purpose — Teriparatide accelerates fracture healing in animals and probably in man. Abaloparatide is a new drug with similar although not identical effects on the teriparatide receptor.
Magnus Bernhardsson, Per Aspenberg
doaj +1 more source
Suitability of teriparatide and level of acceptance of pharmacotherapeutic recommendations in a healthcare management areaSuitability of teriparatide and level of acceptance of pharmacotherapeutic recommendations in a healthcare management area DOI: 10.7399/fh.2016.40.4.9953 [PDF]
Farmacia Hospitalaria, 2016 Objective: To analyse the suitability of teriparatide prescriptions for osteoporosis treatment in a health management area, as well as the level of acceptance of pharmacotherapeutic recommendations made to physicians. Design: A prospective interventional
Maria Rosa Cantudo-Cuenca +5 more
doaj +1 more source
Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide [PDF]
, 2014 Objectives: The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide.
Gallego, Lorena +5 more
core +1 more source
Structure model index does not measure rods and plates in trabecular bone [PDF]
, 2015 Structure model index (SMI) is widely used to measure rods and plates in trabecular bone. It exploits the change in surface curvature that occurs as a structure varies from spherical (SMI = 4), to cylindrical (SMI = 3) to planar (SMI = 0).
Altman +61 more
core +3 more sources
Teriparatide Induced Delayed Persistent Hypercalcemia
Case Reports in Endocrinology, 2014 Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually
Nirosshan Thiruchelvam +3 more
doaj +1 more source
More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery [PDF]
Asian Spine Journal, 2015 Study DesignRetrospective case series.PurposeTo examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis.Overview of LiteratureWe reported that daily subcutaneous injection of teriparatide ...
Seiji Ohtori +19 more
doaj +1 more source
PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases. [PDF]
, 2018 Metastatic breast cancer (BrCa) is currently incurable despite great improvements in treatment of primary BrCa. The incidence of skeletal metastases in advanced BrCa occurs up to 70%.
Wang, Bin, Yang, Yanmei
core +2 more sources